HOME >> BIOLOGY >> NEWS
UT Southwestern researchers identify enzyme deficiency responsible for some sudden infant death cases

DALLAS - August 27, 199 - The discovery by UT Southwestern Medical Center at Dallas researchers that an enzyme deficiency is responsible for some infant deaths attributed to Sudden Infant Death Syndrome (SIDS) could lead to new postnatal testing to identify those at risk.

"Our observations suggest that this deficiency is a severe disorder contributing to early infant death," said Dr. Michael J. Bennett, a professor of pathology and pediatrics at UT Southwestern and director of clinical chemistry at Children's Medical Center of Dallas. "The defect is a deficiency in the SCHAD - short-chain L-3-hydroxyacyl coenzyme A dehydrogenase - enzyme."

The findings were published in the July/August issue of Pediatric and Developmental Pathology.

The deficiency occurs during the breakdown of fatty acids derived from fat stores in the body. The body uses these fats as an energy source when its normal energy supply of glucose, which is converted into glycogen, is used up. In the event of fasting, infants tend to exhaust their limited glycogen supply quickly and begin using the stored fat, Bennett said.

The clinical consequences of SCHAD deficiency -- an inborn error of metabolism -- occur when fatty acids from the stored fats enter the liver and fail to generate energy or to produce ketones. Ketones are a vital energy source for the brain because it cannot use fatty acids, unlike the heart and skeletal muscle, which use fat directly.

"In these infants, fat can get into the liver, but it can't be metabolized and released," Bennett said. "Hence infants' brains starve from the deficit of ketones, and they become comatose."

The researchers examined 150 cases for this study. While only 2 percent were due to SCHAD deficiency, the researchers hope their findings will prevent at least a small portion of the unexpected fatalities previously described as SIDS cases by developing immediate postnatal testing that would identify infants with the enzyme deficienc
'"/>

Contact: Jennifer Haigh
jhaigh@mednet.swmed.edu
214-648-3404
UT Southwestern Medical Center
27-Aug-1999


Page: 1 2

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. RSV can increase the risk of asthma, UT Southwestern researchers find
4. Searle Scholars program awards $240,000 to UT Southwestern researcher
5. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
6. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
7. UT Southwestern researchers reveal mechanisms of smooth-muscle contraction
8. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
9. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
10. UT Southwestern researchers discover link that could aid in treatment of kidney cyst diseases
11. UT Southwestern research halts narcolepsy symptoms

Post Your Comments:
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: